EBS News & Events

Emergent BioSolutions announced the appointment of John Fowler, Jr. to its board of directors effective March 1, 2026. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee.

"In 2026 we look to expand penetration of international markets with our MCM biodefense business, maintain market leadership across the naloxone category and offer new innovative solutions, pursue organic and inorganic growth opportunities that align with our internal capabilities, and remain disciplined on operational efficiencies," said CEO Joe Papa.

The company also forecasts FY26 adjusted net income of $25M-$45M and adjusted EBITDA of $135M-$155M. "Our team remains focused on long-term sustainable value and achieving our vision of enabling several durable and profitable verticals in the Company over time," said CEO Joe Papa.